Skip to content

Elucidating the mechanism of ADAM10/PD-L1 interaction in pancreatic adenocarcinoma cell lines using cellular and computational analyses.

Aug 2026 · Journal of Biomolecular Structure and Dynamics · pp. 1-15 · 0 citations · 43 references
Medicine

TL;DR

This study elucidates the mechanism of ADAM10/PD-L1 interaction in the pancreatic adenocarcinoma cell line, PANC-1, using cellular assays, molecular docking, and molecular dynamics simulations to elucidate how ADAM10 recognizes and interacts with PD-L1, facilitating its cleavage.

Abstract

Targeting the immune checkpoint programmed cell death-ligand 1 (PD-L1) faces diverse challenges against pancreatic ductal adenocarcinoma (PDAC), the most common type of cancer-related death. Shedding of PD-L1 from the tumor cell surface by A Disintegrin And Metalloprotease 10 (ADAM10) may impede the function of antitumor immune cells. Understanding the molecular mechanisms behind this interaction is urgently needed. This study elucidates the mechanism of ADAM10/PD-L1 interaction in the pancreatic adenocarcinoma cell line, PANC-1, using cellular assays, molecular docking, and molecular dynamics (MD) simulations. Cellular assays validated that ADAM10 interacts with PD-L1 and sheds the PD-L1 from the cell surface, generating soluble PD-L1 (sPD-L1). Concurrently, the docking results identified critical residues and potential contact points, providing strong evidence for a stable and specific interaction between ADAM10 and PD-L1. The molecular dynamics (MD) simulations further confirmed the structural integrity of the ADAM10/PD-L1 complex, predicting its compactness and stability. These results elucidate how ADAM10 recognizes and interacts with PD-L1, facilitating its cleavage. Future work can leverage these findings to develop potent cancer immunotherapies that inhibit the ADAM10/PD-L1 interaction and the generation of soluble molecules.

View source

Similar papers

Open access Jul 2026

Temporal Dynamics of PD-L1 Surface in RKO Cells: Characterizing the Reversible Impact of the Small-Molecule Dimerizer BMS-202

These findings suggest that BMS-202-induced changes in surface PD-L1 are acute and reversible, with levels returning to baseline within 24 h post-exposure, and reveal a dynamic regulatory mechanism where small-molecule-induced dimerization triggers rapid protein trafficking and transient surface depletion.

Gohar Sevoyan, Daniel Polianczyk, Siranuysh Grabska et al. · 0 citations
Review Open access Jul 2026

Intracellular PD-L1: Functions, Regulation, and Therapeutic Implications

This review examines the subcellular localization of PD-L1, the mechanisms governing its trafficking and compartmentalization, its compartment-specific biological functions, and the corresponding clinical significance.

Youliang Zhao, Yaqian Qu, Chang-Fu Hao et al. · 0 citations
Open access Aug 2026

Deciphering the regulatory role of ADAM8 in the PDAC tumor microenvironment

It is demonstrated that ADAM8 promotes PDAC aggressiveness by enhancing tumor cell proliferation and migration, activating FAK/Src/STAT3 signaling, and driving macrophage and neutrophil recruitment through cytokine regulation.

Kimia Zandieh, L. Cook, Kai Zhao et al. · 0 citations
Review Aug 2026

PD-1+/PD-L1+macrophages across diseases: a translational continuum from biomarkers to immunotherapeutic targets.

The regulatory mechanisms governing PD-1/PD-L1 expression in macrophages and their biological functions are summarized, the potential of PD-1+/PD-L1+ macrophages as prognostic biomarkers and therapeutic targets are discussed, and targeted intervention strategies for this macrophage subset are examined.

Jinjing Wu, Dan Zhou, Kunpeng Jiang et al. · 0 citations
Open access Jul 2026

Dual-targeting CD73/PD-L1 bifunctional inhibitor: a promising cancer immunotherapy strategy

CP-1 exhibits balanced, dual-nanomolar inhibitory activity against PD-L1 and CD73 and displays potent immunomodulatory effects at the cellular level and serves as a promising lead candidate for developing novel bifunctional agents to advance tumor immunotherapy.

Jing-Jing Du, Sen Wu, Shiyun Cheng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.